{
    "2020-11-20": [
        [
            {
                "time": "",
                "original_text": "暴涨暴跌中：哪些医药股最值得投资？",
                "features": {
                    "keywords": [
                        "医药股",
                        "投资"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558）：获批首个国产ALK抑制剂 NSCLC领域实现两翼齐飞",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "ALK抑制剂",
                        "NSCLC",
                        "国产"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中环股份签单超60亿元合同 这些科技股或表现抢眼",
                "features": {
                    "keywords": [
                        "中环股份",
                        "合同",
                        "科技股"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【国金晨报】贝达药业：恩莎替尼即将上市，公司业绩新增驱动；南微医学：股权激励方案发布，彰显未来发展信心",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩莎替尼",
                        "南微医学",
                        "股权激励"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558）：恩莎替尼即将上市 公司业绩新增驱动",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩莎替尼",
                        "业绩驱动"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}